Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From UnitedHealth Group
The number of drugs included on formulary exclusion lists in the US has surpassed more than 400 at the top three PBMs, representing dramatic growth from just five years ago. Express Scripts recently revealed its 2022 exclusions.
Study will examine prior authorization and other access restrictions at 15 of the largest US commercial payers for a group of 27 drugs.
Study will look at prior authorization, step therapy and required medication switching for drugs considered to be reasonably priced.
Other expected generics include Viatris' Perforomist (formoterol fumarate), Pfizer's Sutent (sunitinib), Sanofi's Jevtana (cabazitaxel) and possibly Boehringer Ingelheim's Pradaxa.
- Other Names / Subsidiaries